Friday, October 10, 2014: 12:30 PM Background. Hepatitis B virus (HBV) infection poses a significant threat to children who have undergone solid organ transplantation. Therefore, completion of the HBV vaccine series is strongly recommended prior to transplantation. However, pediatric transplant recipients in Japan often fail to complete the full series prior to transplantation due to time constraints caused by the lack of a universal HBV vaccination program. Patients often complete the series as a combination of vaccines administered pre and post transplantation. We aimed to determine whether the timing of HBV vaccine influences the serostatus of patients post liver transplant and also evaluate factors that influence serostatus in the largest number of cases.
Background. Hepatitis B virus (HBV) infection poses a significant threat to children who have undergone solid organ transplantation. Therefore, completion of the HBV vaccine series is strongly recommended prior to transplantation. However, pediatric transplant recipients in Japan often fail to complete the full series prior to transplantation due to time constraints caused by the lack of a universal HBV vaccination program. Patients often complete the series as a combination of vaccines administered pre and post transplantation. We aimed to determine whether the timing of HBV vaccine influences the serostatus of patients post liver transplant and also evaluate factors that influence serostatus in the largest number of cases.
Methods. Patients were enrolled after informed consent before and after LT then followed prospectively. HBV vaccines were administered at least 2 weeks prior to LT and ≥1 year after LT if patients' liver function was stable. We collected information on patients who completed a total three doses of HBV vaccine. Serum antibody titers for HBs antibody were investigated and ≥10mIU/ml was considered positive. We compared the demographics and vaccine schedules of patients based on their HBs antibody positivity.
Results. Serological analyses for HBV were performed on 50 patients (median age 4.3 years, underlying disease; biliary atresia 34, metabolic disorder 7, fulminant hepatitis 5, other 4 ) who received a total of three doses of the HBV vaccine and were positive in 60.0% (30/60). There were no meaningful associations with serostatus in age, sex, body weight, underlying disorders, concentration of immunosuppressants, time between test and each immunization and blood tests. The seropositivity rate did not differ according to the timing of 3 doses of HBV vaccination administered pre/post LT (3/0, n = 7, 57.1%, 2/1; n = 8; 62.5%, 1/2; n = 7; 57.1%, 0/3; n = 28; 60.7%).
Conclusion. Pediatric liver transplant recipients achieved a seropositivity rate of approximately 60% after three doses of HBV vaccine regardless of when the doses were administered. Further HBV vaccine strategies are necessary to protect from HBV infection in children who experienced LT.
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